XML Financial LLC Sells 18,053 Shares of Pfizer Inc. $PFE

XML Financial LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 15.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 99,422 shares of the biopharmaceutical company’s stock after selling 18,053 shares during the period. XML Financial LLC’s holdings in Pfizer were worth $2,394,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. BlackRock Inc. boosted its holdings in shares of Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares during the last quarter. State Street Corp grew its position in shares of Pfizer by 0.5% during the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock valued at $7,481,085,000 after acquiring an additional 1,357,756 shares during the period. Geode Capital Management LLC lifted its position in Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after purchasing an additional 1,184,728 shares in the last quarter. Morgan Stanley grew its holdings in Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares during the period. Finally, Norges Bank bought a new stake in Pfizer during the fourth quarter valued at about $1,830,986,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Get Pfizer alerts:

Pfizer Stock Performance

NYSE PFE opened at $28.57 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $29.09. The business has a 50-day moving average price of $25.69 and a 200-day moving average price of $26.31. The firm has a market cap of $162.84 billion, a price-to-earnings ratio of 37.59 and a beta of 0.34.

Pfizer (NYSE:PFE – Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the company earned $0.78 EPS. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.0%. The ex-dividend date of this dividend was Friday, July 24th. Pfizer’s payout ratio is 226.32%.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Finally, HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and dropped their price target for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.28.

Check Out Our Latest Stock Analysis on PFE

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly results supported the move higher. Pfizer’s second-quarter earnings and revenue exceeded analyst expectations, while full-year 2026 EPS guidance remains $2.80–$3.00. The results suggest resilience despite comparisons with the prior year’s COVID-related performance. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Depo-Provera litigation uncertainty has been reduced. Pfizer reached a confidential settlement covering more than 6,000 federal lawsuits alleging a connection between Depo-Provera and intracranial meningioma. Although the financial terms were not disclosed and Pfizer admitted no liability, the agreement removes a significant legal overhang. Pfizer Reaches Confidential Settlement in Depo-Provera Litigation
• Positive Sentiment: Investors are focusing on oncology growth. Padcev, pipeline programs such as PF-08634404 and potential label expansions are central to Pfizer’s effort to offset declining COVID product sales and build longer-term growth. Pfizer’s Oncology Growth Push
• Positive Sentiment: Higher EPS estimates and dividend appeal may be supporting demand. Erste Group Bank increased its FY2026 EPS estimate, while Pfizer’s relatively high dividend yield may attract income-oriented investors seeking defensive healthcare exposure. Pfizer FY2026 EPS Estimate Increased by Erste Group Bank
• Neutral Sentiment: Analysts remain moderately optimistic, but Pfizer has underperformed the S&P 500 over the past year, underscoring continuing concerns about growth and execution. Is Pfizer Stock Underperforming the S&P 500?
• Negative Sentiment: Unusual options activity included purchases of 147,173 put options, about 24% above average. This may reflect bearish positioning or hedging and signals that some traders remain cautious despite the recent rally.

Pfizer Company Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Featured Stories

• Five stocks we like better than Pfizer
• Dutch Bros Sell-Off Creates a Growth Opportunity
• NVIDIA’s MediaTek Bet Shows How It Plans to Defend Its AI Moat
• Is Abercrombie & Fitch’s Hot Streak Just Getting Started?
• Medtronic’s Stars Are Aligning for a Price Recovery

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.